drugset / Trial / NCT04313894

WHARTON JELLY ORIGINATED MESENCHIAL STEM CELL in GONARTHROSIS

NCT04313894 ↗

Phase 2 Unknown 11 enrolled TC Erciyes University
NaSingle-groupOpen-labelTreatment

Summary

Osteoarthritis (OA) is a progressive disease characterized by degeneration of the joint cartilage, which is involved in the immune system leading to proinflammatory cytokine and metalloproteinase release. Knee osteoarthritis is the most common form. The healing is very slow and the damage is not fully recovered, so the degeneration process continues and no treatment modalities completely remove this process. Various methods are used in the treatment of OA and total joint replacement is performed in the patients with OA recently. Ten patients with Kellgren-Lawrence grade II-III knee OA who had been applied for knee pain and received conservative treatment for 6 months and had no benefit will be taken to study. Patients will be assessed 7 (V1-7) times during the study. Clinical, immunologic and radiological treatment effectiveness and clinical improvement will be evaluated at the beginning of the treatment and in all follow-up patients participating in the study.

Timeline

Start
2019-01-01
Primary completion
2019-12-31
Completion
2020-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Wharton Jelly Originated Mesencimal Stem Cell Unknown 1e+08 cells Other

Indications